Method of reducing and treating UVB-induced immunosuppression
Assignee3M Innovative Properties Company
InventorsRichard L. Miller, Anthony A. Gaspari, Joseph A. Gillis
Life of this patent
Estimating the term…
Abstract
Methods of preventing and/or treating UV-induced immunosuppression by administration of immune response modifier compounds are disclosed herein. Suitable immune response modifier compounds include agonists of one or more TLRs.
Claims16
A method of reducing UV-induced immunosuppression comprising administering to a treatment area an immune response modifier compound in an amount effective to inhibit UV-induced immunosuppression,
- wherein to immune response modifier compound is selected from the group consisting of an imidazoquinoline amine, an imidazopyridine amine, a 6,7-fused cycloalkylimidazopyridine amine, a 1,2-bridged imidazoquinoline amine, an imidazonaphthyridine amine, an imidazotetrahydronaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolonaphthyridine amine, a thiazolonaphthyridine amine, and a CpG oligonucleotide.
The method of claim 6 wherein the immune response modifier compound is administered via a topical application vehicle.
A method of treating UV-induced immunosuppression comprising administering to a treatment area an immune response modifier in an amount effective to inhibit UV-induced immnunosuppression,
- wherein the immune response modifier compound is selected from the group consisting of an imidazoquinoline amine, an imidazopyridine amine, a 6,7-fused cycloalkylimidazopyridine amine, a 1,2-bridged imidazoquinoline amine, an imidazonaphthyridine amine, an imidazotetrahydronaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolonaphthyridine amine, a thiazolonaphthyridine amine, and a CpG oligonucleotide.
Dependencies are inferred from the claim text.